Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quest Diagnostics Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $21.1B | |
|---|---|---|
| Revenue (ttm) | 11.8B | |
| Net income (ttm) | 1.1B | |
| EPS (ttm) | $10.0 | |
| Shares out | 110M | |
| P/E (trailing) | 24.5x | |
| P/E (forward) | 16.3x | |
| Dividend | $3.44 (1.40%) | |
| Volume | 730,735 | |
| Beta | 0.54 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $10.79B | $9.88B | $9.25B | $9.87B | $11.04B | +0.6% |
| Gross profit | $4.21B | $3.43B | $3.05B | $3.24B | $3.67B | -3.4% |
| Operating income | $2.75B | $1.38B | $1.29B | $1.40B | $1.60B | -12.7% |
| Net income | $2.00B | $946.0M | $854.0M | $871.0M | $992.0M | -16.0% |
| EPS (diluted) | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 | -13.4% |
| EBITDA | $3.16B | $1.82B | $1.73B | $1.89B | $2.17B | -9.0% |
| R&D | — | — | — | — | — | — |
| SG&A | $1.73B | $1.87B | $1.64B | $1.77B | $1.97B | +3.3% |
Recent company headlines from major financial publishers.
Accretive hospital lab system acquisitions, expansion in advanced and esoteric testing (e.g., Alzheimer's, cancer), and continued realization of cost synergies lead to margin expansion and faster-than-expected organic growth.
Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.3% | $308 | $375 | $396 | $396 | $396 |
| 5.3% | $226 | $261 | $308 | $375 | $396 |
| 6.3% | $179 | $200 | $226 | $261 | $308 |
| 7.3% | $148 | $162 | $179 | $200 | $226 |
| 8.3% | $126 | $136 | $148 | $162 | $179 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
